Irritable bowel syndrome, a common disorder in which bowel habitsare altered in association with abdominal pain or discomfort,has a prevalence of 12 percent among adults in the United Statesand a similar prevalence worldwide.1 By definition, no mechanical,biochemical, or overt inflammatory condition explains the symptoms.Validated, symptom-based criteria for the diagnosis of irritablebowel syndrome are highly predictive in the absence of alarmingsymptoms such as weight loss, fever, and intestinal bleeding.2,3,4The pain or discomfort experienced by patients with irritablebowel syndrome often leads to health care use and a decreasedquality of life.5,6,7 Diarrhea is . . . [Full Text of this Article]
Pathophysiology
Nonpharmacologic Therapies
The Placebo Effect and Irritable Bowel Syndrome
Fiber Supplements
Psychotherapy
Nonspecific Bowel-Directed Therapy
Treatment of Constipation
Antidiarrheal Agents
Specific Therapies
Antispasmodic Agents
Tricyclic Antidepressants
Serotonin-3Receptor Antagonists
Serotonin-4Receptor Agonists
Other Agents
Future Therapies
Approach to Treatment
Source Information
From the Department of Medicine, Division of Gastroenterology, and the Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville.
Address reprint requests to Dr. Mertz at Nashville Gastrointestinal Specialists, 4230 Harding Rd., Suite 309 W., Nashville, TN 37205.
Masand, P. S., Pae, C.-U., Krulewicz, S., Peindl, K., Mannelli, P., Varia, I. M., Patkar, A. A.
(2009). A Double-Blind, Randomized, Placebo-Controlled Trial of Paroxetine Controlled-Release in Irritable Bowel Syndrome. Psychosomatics
50: 78-86
[Abstract][Full Text]
Fumi, A. L, Trexler, K.
(2008). Rifaximin Treatment for Symptoms of Irritable Bowel Syndrome. The Annals of Pharmacotherapy
42: 408-412
[Abstract][Full Text]
Spiller, R, Aziz, Q, Creed, F, Emmanuel, A, Houghton, L, Hungin, P, Jones, R, Kumar, D, Rubin, G, Trudgill, N, Whorwell, P
(2007). Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut
56: 1770-1798
[Abstract][Full Text]
Sayuk, G. S., Elwing, J. E., Lustman, P. J., Clouse, R. E.
(2007). Predictors of Premature Antidepressant Discontinuation in Functional Gastrointestinal Disorders. Psychosom. Med.
69: 173-181
[Abstract][Full Text]
Drisko, J., Bischoff, B., Hall, M., McCallum, R.
(2006). Treating Irritable Bowel Syndrome with a Food Elimination Diet Followed by Food Challenge and Probiotics. J. Am. Coll. Nutr.
25: 514-522
[Abstract][Full Text]
Tack, J, Broekaert, D, Fischler, B, Oudenhove, L V., Gevers, A M, Janssens, J
(2006). A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut
55: 1095-1103
[Abstract][Full Text]
Clouse, R E, Lustman, P J
(2005). USE OF PSYCHOPHARMACOLOGICAL AGENTS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS. Gut
54: 1332-1341
[Full Text]
Motivala, S. J., Sarfatti, A., Olmos, L., Irwin, M. R.
(2005). Inflammatory Markers and Sleep Disturbance in Major Depression. Psychosom. Med.
67: 187-194
[Abstract][Full Text]
Wooltorton, E.
(2004). Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia. CMAJ
170: 1908-1908
[Full Text]
Olden, K. W., Schoenfeld, P. S., Lacy, B. E., Mertz, H.
(2004). Therapy for Irritable Bowel Syndrome. NEJM
350: 1261-1263
[Full Text]